Mochida Pharmaceutical Co., Ltd.
4534.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.99 | 0.01 | -3.63 | 0.09 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 19.42 | 14.73 | 61.80 | 19.06 |
| Quality | ||||
| ROIC | 1.40% | 1.29% | 0.12% | 1.99% |
| Gross Margin | 46.65% | 51.17% | 50.51% | 54.54% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 3.09% | 1.98% | 0.61% | -0.43% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -16.62 | -15.48 | -40.78 | -10.65 |
| Interest Coverage | 2,395.00 | 0.00 | 883.00 | -18.55 |
| Efficiency | ||||
| Inventory Turnover | 0.45 | 0.38 | 0.36 | 0.39 |
| Cash Conversion Cycle | 240.18 | 266.99 | 299.89 | 225.55 |